Literature DB >> 12903012

How should we measure and report radiotherapy-induced xerostomia?

Avraham Eisbruch1, Nelson Rhodus, David Rosenthal, Barbara Murphy, Coen Rasch, Stephen Sonis, Charles Scarantino, David Brizel.   

Abstract

Xerostomia is commonly measured and graded using objective measures of major salivary gland output and observer-rated toxicity grading. The separation between the different grades is somewhat ambiguous in the current toxicity grading systems. We propose a new grading system based primarily on the functional deficits associated with xerostomia. Salivary flow rates have been added as a criterion to the grading system, notwithstanding the weak correlation reported in most studies between the symptoms and objective functional measures. In addition to the observer-rated toxicity grading, recording of patient-reported quality of life, using validated instruments, is encouraged.

Entities:  

Mesh:

Year:  2003        PMID: 12903012     DOI: 10.1016/S1053-4296(03)00033-X

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  45 in total

Review 1.  Assessment of post-radiotherapy salivary glands.

Authors:  S C H Cheng; V W C Wu; D L W Kwong; M T C Ying
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

Review 2.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

Review 3.  World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment.

Authors:  Alessandro Villa; Andy Wolff; Doron Aframian; Arjan Vissink; Jörgen Ekström; Gordon Proctor; Richard McGowan; Nagamani Narayana; Ardita Aliko; Ying Wai Sia; Revan Kumar Joshi; Siri Beier Jensen; Alexander Ross Kerr; Colin Dawes; Anne Marie Lynge Pedersen
Journal:  Clin Oral Investig       Date:  2015-05-22       Impact factor: 3.573

4.  Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.

Authors:  M Lambrecht; D Nevens; S Nuyts
Journal:  Strahlenther Onkol       Date:  2013-01-16       Impact factor: 3.621

5.  Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma.

Authors:  Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Paola Pernici; Pietro Giovanni Gennari
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

6.  Ultrasonic Nakagami-parameter characterization of parotid-gland injury following head-and-neck radiotherapy: a feasibility study of late toxicity.

Authors:  Xiaofeng Yang; Srini Tridandapani; Jonathan J Beitler; David S Yu; Ning Wu; Yuefeng Wang; Deborah W Bruner; Walter J Curran; Tian Liu
Journal:  Med Phys       Date:  2014-02       Impact factor: 4.071

7.  Segmentation of parotid glands from registered CT and MR images.

Authors:  Domen Močnik; Bulat Ibragimov; Lei Xing; Primož Strojan; Boštjan Likar; Franjo Pernuš; Tomaž Vrtovec
Journal:  Phys Med       Date:  2018-06-19       Impact factor: 2.685

8.  Error in the parotid contour delineated using computed tomography images rather than magnetic resonance images during radiotherapy planning for nasopharyngeal carcinoma.

Authors:  Chengxin Liu; Xudong Kong; Guanzhong Gong; Tonghai Liu; Baosheng Li; Yong Yin
Journal:  Jpn J Radiol       Date:  2014-02-21       Impact factor: 2.374

9.  Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.

Authors:  C M van Rij; W D Oughlane-Heemsbergen; A H Ackerstaff; E A Lamers; A J M Balm; C R N Rasch
Journal:  Radiat Oncol       Date:  2008-12-09       Impact factor: 3.481

10.  Ipsilateral irradiation for well lateralized carcinomas of the oral cavity and oropharynx: results on tumor control and xerostomia.

Authors:  Laura Cerezo; Margarita Martín; Mario López; Alicia Marín; Alberto Gómez
Journal:  Radiat Oncol       Date:  2009-09-01       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.